Post

India Poised to Lead Global Pharma Landscape with Focus on Biosimilars and Specialty Medicines: J.P. Nadda, Union Minister for Health & Family Welfare and Chemicals & Fertilizers Pharma Sector should intensify focus on innovation-driven segments says Anupriya Patel Union Minister of State for Health & Family Welfare and Chemicals & Fertilizers; Calls for strengthening of industry-academia collaboration 9th India Pharma Highlights Policy Push and Innovation Driving Sectoral Growth NEW DELHI, 13 April 2026: The 9th edition of India Pharma 2026, the flagship event of the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, Government of India, commenced today in New Delhi. Organized in collaboration with the Federation of Indian Chambers of Commerce and Industry (FICCI) and the Indian Pharmaceutical Alliance (IPA), the two-day conference (April 13–14) brings together key stakeholders from across the global pharmaceutical and healthcare ecosystem, with a strong focus on innovation, self-reliance, and global leadership. Addressing the inaugural session virtually Union Minister of Health & Family Welfare and Chemicals & Fertilizers, Mr J.P. Nadda, emphasized that the platform reflects both the strength and growing global relevance of India’s pharmaceutical sector. He noted that while India has long been recognized as the “pharmacy of the world” due to its leadership in affordable generic medicines, the global landscape is now rapidly shifting towards biologics, biosimilars, and specialty medicines. “In this evolving environment, India is well positioned not only to adapt but to emerge as a global leader,” he stated. Reaffirming the Government’s commitment to fostering innovation and strengthening research capabilities, he highlighted the recently launched Biopharma Shakti Initiative with an outlay of Rs 10,000 crore, aimed at advancing capabilities in biopharmaceutical innovation under the leadership of Prime Minister Shri Narendra Modi. He further underscored complementary initiatives such as the PRIP scheme for promoting research in pharmaceuticals and medical technology, which seek to deepen industry-academia collaboration and accelerate the development of innovative therapies. Strengthening domestic manufacturing remains a key priority, supported by schemes like the Production Linked Incentive (PLI) schemes and the development of bulk drug parks to enhance self-reliance and resilient supply chains. He also reiterated the Government’s commitment to affordable healthcare through initiatives such as the Pradhan Mantri Bharatiya Jan Aushadhi Pariyojana, which continues to expand access to quality medicines at affordable prices across the country. He added that India Pharma 2026 provides a vital platform to foster dialogue, partnerships, and a forward-looking roadmap for the sector.